MedTrace Logo

Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures

NCT01749046 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2017-05-11

No results posted yet for this study

Summary

The purpose of this study is to determine weather Remegal in fixed dosage 1500 mg/daily is effictive and safe in patients with epilepsy with partial seizures

Conditions

  • Epilepsy
  • Simple Partial Seizures
  • Complex Partial Seizures
  • Partial Seizures With Secondary Generalization

Interventions

DRUG

Remegal

Remegal 1500 mg for 12 weeks

Sponsors & Collaborators

  • Valexfarm

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-10-31
Completion
2013-12-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01749046 on ClinicalTrials.gov